Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
Ark Biosciences (Ark) to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018
Ark has submitted an abstract reporting single dose clinical efficacy of its novel RSV F-protein inhibitor Ziresovir, formerly known as AK0529, in infants hospitalized for lower respiratory tract infection with naturally acquired RSV infection. The data to be presented is from the Phase II ‘VICTOR (Viral Inhibition in Children for Treatment of RSV)’ study, “A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection”.
Popular recommendations
-
ArkBio' Ziresovir Included into Pediatric RSV Drug Priority List by WHO2025-07-16
-
ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA2025-06-16
-
ArkBio and Partex Deepen Strategic Collaboration to Advance Novel ATR Inhibitor AK0658 Through AI-Driven Global Development2025-05-30
-
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)2025-05-16
-
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months2025-04-16
-
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China2025-03-24
-
Shanghai Ark Biopharmaceutical Announces Strategic Collaboration with Partex for Partnership and Out-Licensing of Phase 1 Autotaxin Inhibitor AK07072024-12-27
